| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 | Dec-05-17 | Dec-31-16 |
| | 10-K | 10-K | 10-K | 10-K | 8-K | 10-K | 8-K | 10-K |
| Revenues: |
| Total Endoscopy | 0.0 | 0.1 | 45.1 | | | | | |
| Outside of US | | | | 32.6 | | 31.9 | | |
| Other | 63.0 | 42.0 | 5.6 | 28.2 | | 32.5 | | |
| Total revenues | 63.0 | 42.0 | 50.7 | 60.9 | 60.9 | 64.3 | 26.0 | 64.7 |
| Revenue growth [+] | 49.8% | -17.1% | -16.7% | -5.4% | 134.0% | -0.5% | | -4.6% |
| Total Endoscopy | -59.8% | -99.8% | | | | | | |
| Outside of US | | | | 2.5% | | | | |
| Cost of goods sold | 28.0 | 19.8 | 25.0 | 27.7 | 27.7 | 24.6 | 0.0 | 25.3 |
| Gross profit | 35.0 | 22.2 | 25.7 | 33.2 | 33.2 | 39.7 | 26.0 | 39.4 |
| Gross margin | 55.5% | 52.9% | 50.6% | 54.5% | 54.5% | 61.8% | 100.0% | 60.9% |
| Selling, general and administrative [+] | 42.8 | 28.4 | 42.3 | 46.3 | 46.3 | 46.6 | 32.9 | 45.2 |
| Sales and marketing | 24.3 | 17.4 | 28.7 | 32.8 | 32.8 | 32.9 | 32.9 | 31.5 |
| General and administrative | 18.4 | 11.1 | 13.6 | 13.4 | 13.4 | 13.7 | | 13.6 |
| Research and development | 9.5 | 7.7 | 10.4 | 12.2 | 12.2 | 8.3 | 8.3 | 7.8 |
| Other operating expenses | | | | | 7.8 | 7.2 | 7.2 | 7.2 |
| EBITDA [+] | -16.0 | -12.1 | -25.1 | -23.0 | -33.0 | -12.7 | -15.2 | -11.7 |
| EBITDA growth | 32.4% | -51.9% | 8.8% | 81.0% | 117.2% | 9.0% | | 35.3% |
| EBITDA margin | -25.3% | -28.7% | -49.4% | -37.8% | -54.3% | -19.8% | -58.4% | -18.0% |
| Depreciation and amortization | 1.4 | 1.8 | 2.0 | 2.2 | | 2.5 | | 1.9 |
| EBITA | -17.3 | -13.8 | -27.0 | -25.2 | -33.0 | -15.2 | -15.2 | -13.6 |
| EBITA margin | -27.5% | -32.9% | -53.3% | -41.5% | -54.3% | -23.6% | -58.4% | -21.0% |
| Amortization of intangibles | 1.9 | 1.9 | 2.1 | 7.1 | 7.1 | 7.2 | 7.2 | 7.2 |
| EBIT [+] | -19.2 | -15.8 | -29.1 | -32.3 | -40.1 | -22.4 | -22.4 | -20.8 |
| EBIT growth | 21.6% | -45.8% | -9.9% | 44.0% | 78.7% | 8.1% | | 24.4% |
| EBIT margin | -30.5% | -37.6% | -57.4% | -53.1% | -65.9% | -34.9% | -86.3% | -32.1% |
| Non-recurring items [+] | | | -5.6 | 7.8 | | | | |
| Loss (gain) on disposal of assets | | | | 7.8 | | | | |
| Legal settlement | | | -5.6 | | | | | |
| Interest expense | 8.3 | 5.3 | 4.1 | 4.1 | 4.1 | 4.5 | 4.5 | 18.2 |
| Interest expense | 8.3 | 5.3 | 4.1 | 4.1 | 4.1 | 4.5 | 4.5 | 18.2 |
| Other income (expense), net [+] | 3.0 | -1.4 | 0.4 | -1.4 | -1.4 | 0.0 | 0.0 | -1.9 |
| Other non-ooperating expenses | | | | | | 0.0 | | 1.9 |
| Other | 0.1 | -1.4 | 0.4 | -1.4 | -1.4 | 0.0 | 0.0 | -1.9 |
| Pre-tax income | -24.5 | -22.5 | -27.2 | -45.6 | -45.6 | -27.0 | -27.0 | -40.8 |
| Income taxes | 0.2 | 0.1 | 0.3 | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 |
| Tax rate | | | | | | | | |
| Net income | -24.7 | -22.6 | -27.4 | -45.8 | -45.8 | -27.3 | -27.3 | -41.2 |
| Net margin | -39.2% | -53.8% | -54.1% | -75.2% | -75.2% | -42.4% | -104.9% | -63.7% |
| |
| Basic EPS [+] | ($0.82) | ($0.99) | ($1.27) | ($2.31) | ($2.31) | ($2.01) | ($2.01) | ($105.69) |
| Growth | -17.9% | -22.0% | -45.0% | 15.0% | 15.0% | -98.1% | | -30.4% |
| Diluted EPS [+] | ($0.82) | ($0.99) | ($1.27) | ($2.31) | ($2.31) | ($2.01) | ($2.01) | ($105.69) |
| Growth | -17.9% | -22.0% | -45.0% | 15.0% | 15.0% | -98.1% | | -30.4% |
| |
| Shares outstanding (basic) [+] | 30.2 | 22.8 | 21.5 | 19.8 | 19.8 | 13.6 | 13.6 | 0.4 |
| Growth | 32.9% | 5.6% | 8.9% | 45.9% | 45.9% | 3382.9% | | 62.6% |
| Shares outstanding (diluted) [+] | 30.2 | 22.8 | 21.5 | 19.8 | 19.8 | 13.6 | 13.6 | 0.4 |
| Growth | 32.9% | 5.6% | 8.9% | 45.9% | 45.9% | 3382.9% | | 62.6% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |